Rebif (Interferon beta-1a)

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	10

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 10 of 10 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02921035 (ClinicalTrials.gov)	June 30, 2016	29/9/2016	Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)	A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts W ...	Relapsing Multiple Sclerosis (RMS)	Drug: Rebif (Interferon beta-1a)	Merck KGaA, Darmstadt, Germany	Merck Serono Middle East FZ LLC	Completed	18 Years	60 Years	All	594		Hungary;Iran, Islamic Republic of;Korea, Republic of;Kuwait;Lebanon;Morocco;Poland;Saudi Arabia;Germ ...
2	NCT02749396 (ClinicalTrials.gov)	May 2, 2016	20/4/2016	EPID Multiple Sclerosis Pregnancy Study	Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon ß - a Regis ...	Multiple Sclerosis	Drug: Betaseron (Interferonbeta-1b, BAY86-5046), Bayer HealthCare AG;Drug: Extavia (interferonbeta-1 ...	Bayer	EPID Research;Biogen;Merck Serono Europe Ltd;Novartis Pharmaceuticals	Completed	N/A	N/A	Female	2089		Finland
3	NCT02269930 (ClinicalTrials.gov)	October 2014	17/10/2014	Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a)and Rebif® (Interfe ...	An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterf ...	Multiple Sclerosis	Drug: peginterferon beta-1a;Drug: Rebif	Biogen Idec	NULL	Completed	18 Years	45 Years	Both	30	Phase 1	United States
4	NCT01075880 (ClinicalTrials.gov)	May 2009	24/2/2010	Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Mult ...	Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated Wi ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Rebif (Interferon beta-1a)	Merck KGaA	Merck spol.s.r.o., Czech Republic	Completed	18 Years	65 Years	Both	300	N/A	Czech Republic
5	NCT00619307 (ClinicalTrials.gov)	July 2007	8/2/2008	Transition to Rebif New Formulation	A Randomized, Multicenter, Two-arm, Open-label, Phase IIIb Study to Evaluate the Satisfaction in Rel ...	Relapsing Multiple Sclerosis	Drug: Rebif New Formulation + prophylactic Ibuprofen;Drug: Rebif New Formulation + ibuprofen PRN	Merck KGaA	NULL	Completed	18 Years	60 Years	All	117	Phase 3	France;Germany
6	EUCTR2006-005972-42-DE (EUCTR)	20/06/2007	15/08/2007	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in rel ...	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in rel ...	Relapsing multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relaps ...	Trade Name: NA Product Name: Interferon-beta 1a FBS-free/HSA-free, RNF Product Code: NA INN or Proposed ...	Merck Serono International SA	NULL	Not Recruiting			Female: yes Male: yes	120	Phase 3	Germany;France
7	EUCTR2006-005972-42-FR (EUCTR)	12/06/2007	05/04/2007	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in rel ...	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in rel ...	Relapsing multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relaps ...	Trade Name: NA Product Name: Interferon-beta 1a FBS-free/HSA-free, RNF Product Code: NA	Merck Serono International SA	NULL	Not Recruiting			Female: yes Male: yes	120	Phase 3	France;Germany
8	NCT00472797 (ClinicalTrials.gov)	April 2007	10/5/2007	Rebif New Formulation (RNF) Quality of Life (QOL) Study	A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measu ...	Relapsing Multiple Sclerosis	Drug: Rebif New Formulation Non Titrated;Drug: Rebif New Formulation Titrated	EMD Serono	NULL	Completed	18 Years	60 Years	All	232	Phase 3	United States
9	NCT00441103 (ClinicalTrials.gov)	December 2006	26/2/2007	A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a)in Relapsing Remitting Multiple Scler ...	A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Mont ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Rebif® New Formulation (IFN-beta-1a, RNF);Drug: Placebo	Merck KGaA	NULL	Completed	18 Years	60 Years	All	180	Phase 3	Canada;Germany;Italy;Russian Federation;Spain;Switzerland
10	NCT00110396 (ClinicalTrials.gov)	January 2005	6/5/2005	Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis	A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of R ...	Multiple Sclerosis	Biological: Interferon-beta-1a FBS-free/HSA-free	EMD Serono	Pfizer	Completed	18 Years	60 Years	All	260	Phase 3	United States

First Previous1Next Last